Intellipharmaceutics International Inc (IPCI) 3.77

New Post Public Reply Private Reply Replies (0) Message Board

Apr 11, 2014 at 11:27 PM

Intellipharmaceutics International Inc (IPCI) 3.77 $IPCI

Flamel Technologies (FLML) Jumps: Stock Adds 9.8% in Session - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Thu Apr 10, 7:51AM CDT
Flamel Technologies SA was a big mover last session, as its shares rose nearly 10% on the day.

Catalyst Pharmaceutical Partners Inc. (CPRX) Jumps: Stock Up 8.6% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Apr 04, 7:51AM CDT
Catalyst Pharmaceutical Partners Inc. was a big mover last session, as its shares rose nearly 9% on the day.

Reviewing the Top Health Care Equities -- Research on IntelliPharmaCeutics, Delcath Systems, Valeant Pharma and Alkermes
PR Newswire - Fri Mar 21, 4:39PM CDT
On Thursday, March 20, 2014, the NASDAQ Composite ended at 4,319.29, up 0.27%, the Dow Jones Industrial Average gained 0.67% to reach 16,331.05, and the S&P 500 closed at 1,872.01, up 0.60%. The gains were broad based as nine of ten sectors finished higher. The S&P 500 Health Care Sector Index finished the day 0.02% lower at 686.29, whereas, the index has advanced 0.77% in the last one month. Investor-Edge has initiated coverage on the following equities: IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Delcath Systems Inc. (NASDAQ: DCTH), Valeant Pharmaceuticals International Inc. (NYSE: VRX) and Alkermes PLC (NASDAQ: ALKS). Free technical research on IPCI, DCTH, VRX and ALKS can be downloaded upon signing up at:

IntelliPharmaCeutics International (IPCI) Soars: Stock Rises 9.1% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose over 9% on the day.

Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Fri Mar 21, 6:44AM CDT
Can the Rally in IntelliPharmaCeutics (IPCI) Shares Continue?

4 Stocks Under to Trade for Breakouts
at The Street - Fri Mar 21, 5:00AM CDT
These under-$10 stocks are within range of triggering breakout trades.

Intellipharmaceutics -- Amended Form of Proxy for Shareholders Meeting to be Held on March 27, 2014
GlobeNewswire - Wed Mar 19, 4:00PM CDT
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today announced that it has sent to registered shareholders an amended form of proxy for voting at its annual and special shareholders meeting to be held on March 27, 2014 (the "Meeting"

.

Correction - Mackie Research Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Mon Mar 17, 9:59AM CDT
Vancouver, BC, March 17, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.

Jennings Capital Initiates Coverage on Intellipharmaceutics Intl (NASDAQ:IPCI) (TSX:I) with a Speculative Buy Recommendation - Video Research Alert on InvestmentPitch.com
Thomson Reuters ONE - Fri Mar 14, 5:22PM CDT
Vancouver, BC, March 14, 2014 - Investment firm Mackie Research has initiated coverage on Intellipharmaceutics International, (NASDAQ:IPCI) (TSX:I). Analyst Andre Uddin gives the company a speculative buy recommendation and 12-month target of US$11.00, a premium of 140% to the $4.58 price on March 12th, the day the report was issued.

Approvals, Clinical Trial Results, Stock Summaries, Data Publication and Conference Participation - Analyst Notes on Northwest, La Jolla Pharma, Merrimack Pharma, Rosetta, and IntelliPharmaCeutics
PR Newswire - Thu Mar 13, 7:20AM CDT
Today, Analysts Review released its analysts' notes regarding Northwest Biotherapeutics, Inc. (NASDAQ: NWBO), La Jolla Pharmaceutical Co. (NASDAQ: LJPC), Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK), Rosetta Genomics, Ltd. (NASDAQ: ROSG), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Private wealth members receive these notes ahead of publication. To reserve complementary membership, limited openings are available at: http://www.AnalystsReview.com/register

IntelliPharmaCeutics (IPCI) Jumps: Stock Up 8.9% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Tue Mar 11, 7:51AM CDT
IntelliPharmaCeutics International Inc. was a big mover last session, as its shares rose nearly 9% on the day.

5 Stocks Ready for Breakouts
at The Street - Fri Mar 07, 1:19PM CST
These stocks look poised to break out and trade higher from current levels.

Intellipharmaceutics to Present at Two Upcoming Investor Conferences
GlobeNewswire - Tue Mar 04, 4:00PM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, announced today that the Company is scheduled to present at the following two upcoming conferences.

Intellipharmaceutics posts higher net loss in 2013
M2 - Wed Feb 19, 6:11AM CST
Canadian pharmaceutical company Intellipharmaceutics International Inc (NasdaqCM:IPCI) (TSX:I) stated on Tuesday a net loss of USD11.5m (USD0.58 per common share) for the year ended 30 November 2013.

Intellipharmaceutics Announces 2013 Year End Results
GlobeNewswire - Tue Feb 18, 6:05AM CST
Intellipharmaceutics International Inc. (Nasdaq:IPCI) (TSX:I), a pharmaceutical company specializing in the research, development and manufacture of novel and generic controlled-release and targeted-release oral solid dosage drugs, today reported the results of operations for the year ended November 30, 2013. All dollar amounts referenced herein are in United States dollars unless otherwise noted.

Biotech News for Advancing Pharma Stocks: Company's Test Results Surpass Expectations For $3.5 Billion ADHD Market
PR Newswire - Tue Feb 04, 8:05AM CST
Market Briefing for leading pharma advancers along with clinical data reveals biotech company is on the verge of fulfilling glaring market need: Amarantus Bioscience Holdings, Inc. (OTCQB: AMBS), Pfizer Inc. (NYSE: PFE), IntelliPharmaCeutics International Inc. (NASDAQ: IPCI), Alcobra Ltd. (NASDAQ: ADHD), Horizon Pharma, Inc. (NASDAQ: HZNP) and Vanda Pharmaceuticals, Inc. (NASDAQ: VNDA)

Intellipharmaceutics International Inc awarded first profit-share of USD3.1m from Par Pharmaceuticals Inc for sales of 15 and 30 mg generic Focalin XR
M2 - Tue Feb 04, 4:33AM CST
Pharmaceutical company Intellipharmaceutics International Inc (TSX:I) said on Monday that it has received the first payment of USD3.1m relating to commercial sales of dexmethylphenidate hydrochloride extended-release capsules by its licensee Par Pharmaceutical Inc.

Intellipharmaceutics Receives $3.1 Million From Par Pharmaceuticals, Inc.
GlobeNewswire - Mon Feb 03, 6:00AM CST
- First Profit-Share Payment on 15 and 30 mg Generic Focalin XR(R) Sales

5 Stocks Poised for Breakouts
at The Street - Fri Jan 10, 12:20PM CST
These stocks look ready to break out and trade higher from current levels.

Healthcare Sector Announces Voluntary Recalls, Scheduled Presentations and Offering Programs - Research Report on Baxter, Incyte, Horizon Pharma, POZEN, and IntelliPharmaCeutics
PR Newswire - Mon Dec 02, 7:00AM CST
Today, Analysts' Corner announced new research reports highlighting Baxter International Inc. (NYSE: BAX), Incyte Corporation (NASDAQ: INCY), Horizon Pharma, Inc. (NASDAQ: HZNP), POZEN Inc. (NASDAQ: POZN), and IntelliPharmaCeutics International Inc. (NASDAQ: IPCI). Today's readers may access these reports free of charge - including full price targets, industry analysis and analyst ratings - via the links below.

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Pye-Barker's Bold Play in Florida Fire Safety Market

A Strategic Spark in Fire Protection Well, here's a move that lights up the fire protection sector. Pye-Barker Fire & Safety, known for being the top dog in U.S. fire safety services, decided to scoop up St. John's Fire Equipment down in Florida. Let's just say, they're not putting out any fires here—more like stoking a strategic blaze. This acquisition positions...

Hello Group Gears Up for Q3 Earnings Release

Anticipation Builds for Hello Group's Q3 Results Time flies when you're watching stocks, and believe me, December's about to get red hot for Hello Group Inc. (NASDAQ: MOMO). With their unaudited financial results for the third quarter of 2026 hitting the wire before the U.S. markets open on December 7, there's enough speculation cooking to rival a Thanksgiving feast....

Illinois House Democrats Surge with Historic Gaines

Turning the Election Tide in Illinois Damn, if you're not paying attention to what's shaking in Illinois, it's time to listen up. The Democrats under Speaker Emanuel "Chris" Welch are strutting their stuff, leaving an indelible mark on the political landscape. An eye-popping $35 million in campaign dough was raised, safeguarding every Democratic incumbent and managing to...

Xinjiang Co-op Elevates Walnut Farmers, Markets Expand

From the Gobi Desert to the Global Market You ever hear about walnuts from the Gobi Desert? It sounds like a tale spun over too many drinks, but here we are, talking about folks in Xinjiang crafting an empire out of nuts. Not just any nuts, mind you—walnuts, lovingly nurtured under the sun and cold nights in Kuqa. They’ve carved out a niche in a corner of the world...

Pharmaceutical Navigator ASTHO's Podcast Earns Bronze Anthem Award

An Award to Nod At: ASTHO's Public Health Triumph The world of public health isn't generally where you'd find shiny accolades flying around, but when they do, it's worth taking notice. Recently, ASTHO’s podcast, the Public Health Review Morning Edition, snagged a Bronze Anthem Award. Sure, it isn't the gold trophy, but in this high-stakes arena, any medal's a feat! More...

Qfin Holdings Faces Class Action Over Stock Drop

Qfin Holdings' Troubled Waters Look, when a stock tanks by nearly 19% overnight, it isn't because of some fluke. And that's precisely what's got Qfin Holdings, Inc. investors gritting their teeth and lawyers sharpening their pencils. Deep Dive into Allegations For those keeping score, we're talking about serious allegations here: between March 18, 2026, and August 25,...

NSING's Bluetooth Milestone: A Signal for Investors

The Bluetooth Bonanza: NSING Technologies' Big Win Amidst the bustling lanes of the semiconductor sector, NSING Technologies just threw down a whopper of an announcement—over 250 million Bluetooth chips shipped, all well-knitted with Ceva's technology. This isn’t just another milestone; it's a clarion call for anyone keeping an eye on the evolving landscape of...

Mondego Bio Charges Ahead with Cancer Therapy Trials

Cracking Cancer's Code: Mondego's Bold Move Big news from Portugal today—a quiet town called Cantanhede is now the epicenter of a potential game-changer in cancer therapy. Mondego Bio, with its small-molecule innovator MB?388, is diving headfirst into a Phase 1 clinical study. If you're scratching your head about the significance, let me spell it out: this is an attempt...

Coronation Securities: Pioneering Digital Brokerage in Nigeria

Coronation Securities: A Digital Revolution Ah, Nigerian financial markets have found themselves a trailblazer, folks. Meet Coronation Securities Limited, recently crowned the 'Fastest Growing Digital Brokerage Platform – Nigeria' at the 2026 Global Brand Awards. Now, that's a nod from Global Brands Magazine worth sitting up for. Turning the Tide with Tech In an...

BDX Flexes Financial Muscle with Strong FY26 Results

BD's Performance in FY2026: A Strong Finish Y'know, it's not every day we see a giant like Becton, Dickinson and Company (NYSE: BDX) grinding out some impressive numbers. But, here we are. They just wrapped up fiscal 2026, and it's looking like they ain't just skating by. We're talking a 5.4% bump in fourth quarter revenue, landing them at a cool $5.3 billion. Not too...